J&J/Legend’s Carvykti Data Show Earlier-Line Efficacy As Commercial Headwinds Remain

 
• By Alaric DeArment
J&J/Legend announced positive results from the Phase III CARTITUDE-4 study • Source: Shutterstock

More from Immuno-oncology

More from Anticancer